Skip to main navigation
Skip to search
Skip to main content
Western Sydney University Home
Research Profiles Login
Link opens in a new tab
Search content at Western Sydney University
Home
Profiles
Research outputs
Projects
Datasets
HDR theses
Activities
Press/Media
Prizes
Subjects
Research units
CD20 inhibitors : rituximab
Kevin D. Pile
, Garry G. Graham
, Stephen M. Mahler
Western Sydney University
School of Medicine
Research output
:
Chapter in Book / Conference Paper
›
Chapter
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'CD20 inhibitors : rituximab'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Rheumatoid Arthritis
66%
Inflammatory Arthritis
66%
Neoplasm
33%
Combination Therapy
33%
Clinical Trial
33%
Disease Modifying Antirheumatic Drug
33%
Autoimmune Disease
33%
Monoclonal Antibody
33%
Chelating Agent
33%
Antirheumatic Agent
33%
Radioisotope
33%
Diseases
33%
Ocrelizumab
33%
Ibritumomab Tiuxetan
33%
Ofatumumab
33%
Indium
33%